Asana Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Asana Inc. trades at $9.1 (market cap $2.13B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.81B). The key difference: Asana Inc. is the larger of the two by market cap, and Asana Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ASAN | RXRX | |
|---|---|---|
Market Cap | $2.13B | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $6.79 |
52-Week Low | $5.46 | $2.84 |
Enterprise Value | $1.96B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.23, down slightly by 0.32% today. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, revenue growth is robust with fiscal 2025 revenue reaching $723.88 million, but the company remains unprofitable with a net loss of $255.54 million. Recent news highlights AI product innovation and a strategic partnership with Norway's sovereign wealth fund, signaling positive business momentum.
The outlook for Asana is mixed. Analyst consensus leans bullish with a $10.33 price target, but persistent losses and intense competition from tech giants pose significant risks. Upside potential hinges on continued revenue growth and path to profitability, while downside risks include margin pressure and execution challenges in a competitive SaaS market.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →